3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Stomach Neoplasms
12
Colorectal Neoplasms
10
Adenocarcinoma
6
Breast Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Sarcoma
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
pembrolizumab
35
Nivolumab
13
Cyclophosphamide
11
fludarabine
9
aldesleukin
9
atezolizumab
7
Magnetic Resonance Spectroscopy
7
Carboplatin
7
Specimen Handling
6
Ipilimumab
6
Early Intervention, Educational
6
Cisplatin
6
Trastuzumab
5
Paclitaxel
5
Methods
5
Biopsy
5
Bevacizumab
5
durvalumab
4
Vaccines
4
Surveys and Questionnaires
4
Radiotherapy
4
Papillomavirus Vaccines
4
Interleukin-2
4
Docetaxel
4
tisotumab vedotin
3
spartalizumab
3
fludarabine phosphate
3
cemiplimab
3
aflibercept
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
trastuzumab deruxtecan
×
Gastrointestinal
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled